-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck KGaA's SpringWorks Gets UK Clearance for Plexiform Neurofibromas Therapy

MT Newswires·12/11/2025 10:58:11
Listen to the news
10:58 AM EST, 12/11/2025 (MT Newswires) -- The UK's Medicines and Healthcare products Regulatory Agency on Thursday approved the marketing authorization for SpringWorks Therapeutics Ireland's Mirdametinib. The Merck KGaA (MRK.F) subsidiary's medicine, also known as Ezmekly, is now cleared for the treatment of plexiform neurofibromas in children aged two and above, adolescents, and adults with neurofibromatosis type 1 in the UK. The British regulator noted that it will continue to closely monitor the medicine's safety and effectiveness.